The company's lead asset, BMF-219, a covalent menin inhibitor targeting diabetes, has been the subject of intense scrutiny following a clinical hold earlier this year. This comprehensive analysis ...

GSA Capital Partners LLP lowered its stake in shares of Biomea Fusion, Inc. (NASDAQ:BMEA – Free Report) by 36.8% during the third quarter, according to the company in its most recent disclosure with ...

Announced that World Health Organization (WHO) has approved “icovamenib” as the International Nonproprietary Name (INN) for its lead product candidate BMF-219, and that the United States ...

The company’s investigational drug, icovamenib (BMF-219), has shown encouraging results in early-phase trials for diabetes. The unique covalent mechanism of action, which targets pancreatic ...

An announcement from Biomea Fusion ( (BMEA) ) is now available. Biomea Fusion, Inc. showcased promising preclinical data on its innovative ...

that a full clinical hold has been placed on Biomea's ongoing Phase I/II clinical trials of the Company's investigational covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes (COVALENT-111 ...

Announced that World Health Organization (WHO) has approved "icovamenib" as the International Nonproprietary Name (INN) for its lead product candidate BMF-219, and that the United States Adopted ...